相关实验视频
Updated: May 24, 2025

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.2K
苦味受体激活剂诱导乳头甲状腺癌中的亡
Kimberly Wei1, Brianna L Hill1, Joel C Thompson1
1Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Head & neck
|March 5, 2025
概括
皮皮甲状腺癌 (PTC) 细胞中苦味受体 (T2Rs) 的激活会诱导细胞亡,并改善患者的生存率. 较高的TAS2R表达与更好的结果相关,这表明T2R激动剂在甲状腺癌中的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳头甲状腺癌 (PTC) 是最常见的甲状腺恶性瘤,其特点是显著的复发率.
- 苦味受体 (T2Rs) 和它们的基因 (TAS2Rs) 参与调节固体瘤中的细胞存活.
- 在PTC细胞中T2Rs的表达和功能作用在很大程度上仍未被探索.
研究的目的:
- 为了研究T2Rs在人类PTC细胞系中的表达.
- 确定苦酸激素激活对PTC细胞活力和亡的功能影响.
- 探索PTC中T2R表达和患者生存结果之间的相关性.
主要方法:
- 在三种PTC细胞系 (MDA-T32,MDA-T68,MDA-T85) 中使用RT-qPCR和免疫光学分析T2R基因和蛋白质表达.
- 通过活细胞成像测量细胞内对苦药激动剂的反应.
- 使用晶体紫色染色和caspase 3/7激活试验评估细胞活力和细胞亡.
- 对TAS2R14表达和患者无进展生存率之间的相关性分析.
主要成果:
- 发现TAS2R14在所有检查的PTC细胞系中都具有高度表达.
- 通过五种不同的苦味激素激活,在细胞质和线粒体两部分都引起了显著的反应.
- 暴露于苦酸激动剂显著降低了细胞活力,并在PTC细胞中诱导了细胞亡.
- 在PTC患者中,较高的TAS2R14表达和改善的无进展生存期之间观察到显著的正相关性 (p < 0.05).
结论:
- 通过苦酸激动剂激活T2Rs会在PTC细胞中触发亡.
- 提升的T2R表达与甲状腺癌患者的增强生存结果有关.
- 这些发现突显了T2R激动剂在治疗甲状腺癌方面的潜在治疗效用.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
The Intrinsic Apoptotic Pathway
5.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.9K
Synthesis and Regulation of Thyroid Hormones
4.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.1K
Phagocytosis of Apoptotic Cells
3.3K
Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or immature dendritic cells. Non-professional phagocytes such as epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes.
Normal cells contain receptors that prevent them from being recognized...
Normal cells contain receptors that prevent them from being recognized...
3.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171

